目的 探讨谷红注射液联合阿加曲班治疗急性脑梗死的疗效及其对血清超氧化物歧化酶（SOD）和丙二醛（MDA）水平影响。方法 选取2018年1月-2020年1月保定市第二中心医院收治的急性脑梗死患者104例作为研究对象，将患者随机分为对照组和观察组，每组各52例。对照组患者静脉滴注阿加曲班注射液，60 mg阿加曲班注射液以适当量的氯化钠注射液稀释，经24 h持续静脉滴注治疗2 d，然后10 mg/次治疗5 d，早晚各1次。观察组在对照组基础上静脉滴注谷红注射液，20 mL/次，溶于氯化钠注射液250 mL中静脉滴注，1次/d。两组患者持续治疗14 d。观察两组患者的临床疗效，同时比较两组治疗前后的Barthel指数（BI）和美国国立卫生研究院卒中量表（NIHSS）评分、血清SOD和MDA水平，以及血浆黏度（PV）、全血黏度（WBV）、红细胞压积（HCT）、纤维蛋白原（FIB）水平。结果 治疗后，对照组和观察组总有效率分别80.77%和94.23%，两组总有效率比较差异具有统计学意义（P<0.05）。治疗后，两组BI评分显著升高，NIHSS评分降低（P<0.05）；且观察组NIHSS评分和BI评分显著优于对照组（P<0.05）。治疗后，两组MDA水平显著降低，SOD水平显著升高（P<0.05）；治疗后，观察组血清SOD和MDA水平显著优于对照组（P<0.05）。治疗后，两组PV、WBV、HCT、FIB水平均明显降低（P<0.05）；治疗后，观察组PV、WBV、HCT、FIB水平显著低于对照组（P<0.05）。结论 谷红注射液联合阿加曲班治疗急性脑梗死具有较好的临床疗效，能够改善患者血清SOD和MDA水平，值得临床推广应用。

Objective To investigate the effect of Guhong injection combined with agatreban on acute cerebral infarction and its effect on serum SOD and MDA levels. A total of 104 patients with acute cerebral infarction admitted to the Second Central Hospital of Baoding City from January 2018 to January 2020 were selected as the research subjects, and the patients were randomly divided into control group and observation group, with 52 cases in each group. Methods Patients in the control group were iv administered with Argatroban Injection, 60 mg Argatroban Injection was diluted with appropriate amount of sodium chloride injection for 24 h continuous intravenous infusion for 2 d, and then 10 mg/time for 5 d, once in the morning and once in the evening. Patients in the observation group were iv administered with Guhong Injection intravenously, 20 mL/time, dissolved in 250 mLsodium chloride injection intravenously, once daily. Patients in two groups were treated for 14 d. Clinical efficacy of two groups was observed, and the BI score, NIHSS score, serum levels of SOD, MDA, PV, WBV, HCT, and FIB before and after treatment were compared. Results After treatment, the total effective rate of the control group and the observation group was 80.77% and 94.23%, respectively, and the total effective rate of the two groups was statistically significant (P<0.05). After treatment, BI score in two groups was significantly increased, while NIHSS score was decreased (P<0.05). And the NIHSS and BI scores in the observation group were significantly better than those in the control group (P<0.05). After treatment, the levels of PV, WBV, HCT and FIB in two groups were significantly decreased (P<0.05). After treatment, the levels of PV, WBV, HCT and FIB in observation group were significantly lower than those in control group (P<0.05). After treatment, the MDA level was significantly decreased, but the SOD level was significantly increased (P<0.05). After treatment, the levels of SOD and MDA in serum of observation group were significantly better than those of control group (P<0.05). Conclusion Guhong Injection combined with agartreban in treatment of acute cerebral infarction has a good clinical effect, can improve serum SOD and MDA levels, worthy of clinical application.

R971